Mitomed Pharma is developing next-generation highly innovative cancer treatments with potential to be best-in-class
Our technology is designed to target a critical mechanism inside tumor cells that enables them to proliferate.
INNOVATIVE DUAL SPECIFICITY CANCER THERAPIES
We are advancing a novel class of cancer therapeutics designed to target a previously unknown vulnerability of many cancer types. Cancer cells are under oxidative stress due to their high metabolism which is required for proliferation. We develop drugs that are systemically administered, selectively enter cancer cells, and disrupt a key regulator of iron acquisition and reactive oxygen species. Upon entering the cancer cell, our drugs traffic to the mitochondria (the powerhouse of the cell) and disrupt a key protein-protein interaction that protects cancer cells from that oxidative stress, leading to cell death.
Mitochondria protect cancer cells from stress:
we kill cancer cells by disrupting that protection.
Our team of experienced scientists invented this proprietary approach to selectively target tumor cells and create the future for cancer treatment.
Focus on Cancer
Despite advances in multiple therapeutic approaches (chemotherapy, surgery, radiation therapy, immunotherapy), many cancers become refractory to effective treatment. Further, these treatments are often accompanied by severe side effects. New cancer-targeted drugs with minimal side effects are desperately needed.
We are at a breakthrough moment for many hard-to-treat forms of cancer
Mitomed is leveraging years of fundamental research to develop new treatments that could potentially benefit everyone impacted by cancer. With no side effects in experimental animals, these new treatment approaches could be used alone or in combination with traditional therapies, such as immunotherapy or chemotherapy, and potentially improve our chances of cancer cure.
Our Vision
Mitomed was founded to bring our proprietary technology to the clinic with the goal of developing effective targeted treatments for cancer without the severe side effects that accompany many of today’s treatments. Based on our pre-clinical data in multiple cancer models, we believe our compounds may be effective across many hard-to-treat cancers.
Our leaders each have over 30 years of drug development and business development experience that can guide our teams to develop innovative drugs and solutions to cure cancer, while their commitment to innovation fuels our culture.
With passion, expertise, and perseverance, we are forging a path towards innovative treatments for all people impacted by cancer.
Our History
Our scientific founders discovered a potentially revolutionary treatment for cancer, a new class of rationally designed drugs with high specificity for cancer cells and a novel target, NAF-1 (also called CISD2). They validated NAF-1 as an important cancer target and developed new drugs to specifically inactivate this protein only in cancer cells. Mitomed Pharma was founded in 2023 to develop and advance these novel drugs. Today, the Mitomed team is leveraging these critical insights to expand the company and advance our lead compound into clinical trials and beyond.
Mitomed © Copyright. All rights reserved.
We need your consent to load the translations
We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.